The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Piramal Pharma’s manufacturing facility located at Sellersville (USA). With the issuance of the EIR, the inspection has now been successfully closed by the USFDA.
Earlier, USFDA had conducted a Good Manufacturing Practices (GMP) inspection of Piramal Pharma’s Sellersville (USA) facility from May 04, 2026 to May 08, 2026. At the conclusion of the inspection, USFDA issued a Form-483, with three observations.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
